Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework
Current Opinion in Psychology,
Год журнала:
2025,
Номер
62, С. 101992 - 101992
Опубликована: Янв. 16, 2025
Язык: Английский
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Journal of Psychoactive Drugs,
Год журнала:
2025,
Номер
unknown, С. 1 - 13
Опубликована: Янв. 29, 2025
The
ever-changing
landscape
surrounding
legality
and
accessibility
of
psychedelics
their
increasing
popularity
make
it
imperative
to
better
understand
the
nature
psychedelic
use
by
general
population.
To
this
end,
1,486
eligible
respondents
(Mage
=
29.58,
67.1%
male)
residing
in
United
States
completed
an
online
survey
designed
assess
types
used,
methods
administration
dosing,
frequency
use,
intentions
for
context/environments
which
they
are
perceived
acute
effects,
those
effects
distress
about
them,
residual
them.
Respondents
predominantly
endorsed
using
MDMA,
LSD,
DMT,
psilocybin.
predominant
were
oral.
Most
reported
recreational
purposes.
most
hallucinations,
increased
heart
rate,
positive
mood,
visual
tracers,
while
headaches/migraine,
dry
mouth,
nausea,
anxiety.
Participants
distressed
negative
mood
states,
vomiting,
nausea
when
under
psychedelics,
but
mean
ratings
low.
These
results
can
help
inform
clinical
trials,
reform
policy
regarding
legal
access
track
changes
these
metrics
as
sociocultural
landscapes
continue
shift.
Язык: Английский
Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use
British Journal of Pain,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 11, 2025
Psychedelic
substances
have
shown
preliminary
efficacy
for
several
neuropsychiatric
disorders
and
are
currently
being
investigated
chronic
pain
conditions.
However,
few
studies
outcomes
of
naturalistic
psychedelic
use
among
individuals
with
pain,
none
assessed
psychedelic-related
changes
in
substance
patterns
this
population.
In
a
cross-sectional
survey
adults
who
reported
using
psychedelics
to
self-treat
condition
(
n
=
466;
46.1%
women),
we
changed
self-reported
on
physical
mental
health
following
psychedelic.
Most
(86.3%;
391/453)
indicated
that
they
ceased
or
decreased
one
more
non-psychedelic
“as
result
of”
use,
21.2%
83/391)
the
decrease
persisted
than
26
weeks
after
use.
Alcohol
(71.1%;
226/318)
prescription
opioids
(64.1%;
100/156)
had
highest
proportions
ceased/decreased
Illicit
(27.8%;
22/79)
cannabis
(21.5%;
78/362)
increased/initiated
multivariate
regression
modeling,
having
motivation
reduce
one’s
was
positively
associated
ceasing/decreasing
p
<
.001).
Perceptions
were
broadly
positive,
psilocybin
be
most
effective
both
symptoms.
Although
limited
by
study
design,
findings
from
large
sample
merit
future
investigation
into
benefits
risks
pain.
Язык: Английский
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial
Frontiers in Pain Research,
Год журнала:
2025,
Номер
6
Опубликована: Март 18, 2025
Fibromyalgia
(FM)
is
the
prototypical
nociplastic
pain
condition,
characterized
by
widespread
and
issues
with
cognition,
mood,
sleep.
Currently,
there
are
limited
treatment
options
available
that
effectively
treat
FM
symptoms.
Psilocybin-assisted
therapy
(PAT)
an
emerging
combined
drug-therapy
intervention,
but
no
studies
to-date
have
investigated
PAT
for
FM.
Here,
we
report
findings
from
open-label,
pilot
clinical
trial
of
(N
=
5).
In
conjunction
psychotherapy
(two
preparatory,
four
integration
sessions),
participants
received
two
doses
oral
psilocybin
(15
mg
25
mg)
delivered
weeks
apart.
Regarding
safety
(primary
outcome),
were
transient
elevations
blood
pressure
or
heart
rate
during
dosing
which
normalized
end
treatment,
serious
adverse
events.
Four
five
reported
headaches
following
dosing.
Compared
to
baseline,
clinically
meaningful
improvements
in
secondary
outcomes
one
month
their
second
dose
(reported
as
Cohen's
d):
severity
[d
-2.1,
95%
CI(-3.7
-0.49)],
interference
-1.8,
CI
(-3.27
-0.24)],
sleep
disturbance
-2.5,
(-4.21
-0.75)].
Using
Patient
Global
Impression
Change,
participant
symptoms
"very
much
improved,"
"much
"minimally
improved."
We
stopped
recruitment
early
because
concerns
about
generalizability
changes
FDA
guidance
psychedelic
trials
occurred
data
collection.
This
small
open-label
preliminarily
supports
well-tolerated
people
FM,
establishing
a
basis
larger
randomized
controlled
trials.
ClinicalTrials.gov,
identifier,
(NCT05128162).
Язык: Английский
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics
Journal of Psychopharmacology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 31, 2025
Background:
Classic
psychedelics
such
as
psilocybin
and
lysergic
acid
diethylamide
are
anecdotally
associated
with
the
phenomenon
of
“psychedelic
afterglow,”
a
set
predominantly
pleasant,
temporary
psychological
effects
reported
after
acute
have
subsided.
Since
post-acute
crucial
for
therapeutic
use
psychedelics,
an
instrument
to
systematically
assess
subacute
“afterglow”
is
needed.
Aims:
To
create
validate
questionnaire
quantify
psychedelics.
Methods:
An
international
online
survey
was
conducted
in
English
German.
Participants
who
had
consumed
psychedelic
(
N
=
1323)
or
another
non-psychedelic
substance
(control
group,
157)
within
past
4
weeks
were
included.
initial
list
97
items
progressively
reduced
24
items.
Results:
A
5-factor
structure
best
fit
data
showed
high
internal
consistency.
The
factors
included
(1)
vitality,
(2)
transpersonal
aspects,
(3)
inspiration/creativity,
(4)
interpersonal
relationships,
(5)
relationship
nature.
final
24-item
version
Afterglow
Inventory
(AGI)
effectively
differentiated
between
group
control
group.
overall
AGI
score
positively
correlated
intensity
r
0.165;
p
<
0.001)
positive
valence
0.251;
effects.
Conclusions:
novel
scale
quantifying
(“afterglow”)
could
lead
better
understanding
interplay
acute,
subacute,
long-term
Insights
also
be
gained
into
how
different
substances,
dosages,
extra-pharmacological
factors,
psychotherapy,
might
influence
outcomes.
Язык: Английский
Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Год журнала:
2025,
Номер
unknown, С. 111361 - 111361
Опубликована: Апрель 1, 2025
Studies
of
psychedelic
use
in
naturalistic
and
clinical
settings
have
suggested
safety
mental
health
benefits
for
adults
with
histories
childhood
maltreatment.
Acute
psychological
mechanisms
that
predict
therapeutic
this
population,
however,
yet
to
be
determined.
Two
common
group
-
organized
ceremonies
raves
or
other
electronic
dance
music
events
might
facilitate
effects
because
the
unique
psychosocial
environments
they
comprise.
This
prospective,
longitudinal
study
sought
investigate
2
primary
questions:
first,
whether
maltreatment
planning
drugs
intent
at
would
see
enduring
after
their
experiences;
second,
subjective
dimensions
acute
experience
associated
lasting
benefits.
Eighty-five
participants
completed
self-report
measures
month
before,
within
days
after,
approximately
months
a
planned
ceremony
rave
assessing
history;
trauma
symptoms,
internalized
(trait)
shame,
connectedness
baseline
follow-up;
various
experience.
Mean
scores
posttraumatic
stress
disorder
(PTSD)
complex
PTSD
trait
social
connectedness,
general
significantly
improved
from
2-month
follow-up
(ds
=
0.73-1.12).
Longitudinal
changes
outcomes
correlated
These
findings
implications
regarding
both
potential
benefit
among
as
well
action
psychedelics.
Язык: Английский
Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement
BMJ Open,
Год журнала:
2025,
Номер
15(4), С. e095992 - e095992
Опубликована: Апрель 1, 2025
Introduction
Prolonged
grief
disorder
(PGD)
represents
a
substantial
public
health
issue,
especially
in
oncology
settings
where
it
affects
up
to
30%
of
bereaved
carers.
Current
best-practice
treatments
are
lengthy,
and
50%
participants
have
persistent
PGD.
Building
on
encouraging
recent
research
with
psychedelic-assisted
therapies,
the
Psilocybin-Assisted
suppoRtive
psychoTherapy
IN
treatment
prolonged
Grief
(PARTING)
trial
is
first
study
consider
psilocybin-assisted
psychotherapy
as
potential
for
grief.
Methods
analysis
PARTING
an
open-label
pilot
approximately
15
people
cancer-related
It
aims
investigate
feasibility,
safety,
acceptability,
participant
experience
participant-reported
therapeutic
effects.
Over
5-week
intervention
period,
will
undergo
three
preparation
sessions
before
receiving
psychoactive
(25
mg)
dose
psilocybin
alongside
non-directive
supportive
guidance,
followed
by
four
integration
sessions.
All
be
delivered
psychologist
either
nurse
or
Indigenous
Therapist.
An
artificial
intelligence-assisted
tool
used
create
artwork
participants’
psychedelic
experience.
Outcomes
investigated
over
12-month
follow-up
period.
Feasibility
assessed
through
recruitment/retention
rates
completion
assessments.
Safety
evaluated
via
adverse
events
12
months
comparison
physiological
measures
(vital
signs,
biochemistry,
haematology,
ECG)
recorded
during
screening
1
day
after
dose.
Qualitative
thematic
semistructured
interviews
therapists
assess
acceptability
treatment.
Diagnostic
clinical
PGD
quantitative
effects
also
being
collected.
Participant-reported
include
severity,
depression,
anxiety,
avoidance,
psychological
flexibility,
connectedness,
quality
life.
Ethics
dissemination
approval
has
been
obtained
from
QIMR
Berghofer
Medical
Research
Institute
Human
Committee
(P3801).
Dissemination
results
occur
conference
presentations,
peer-reviewed
publications
media.
Trial
registration
number
Australian
New
Zealand
Clinical
Trials
Registry
(ACTRN12623000827639).
Язык: Английский
Ayahuasca ceremonies, relationality, and inner-outer transformations to sustainability. Evidence from Takiwasi Center in Peru
Ecosystems and People,
Год журнала:
2024,
Номер
20(1)
Опубликована: Апрель 18, 2024
The
use
of
psychedelic
substances
is
increasingly
associated
with
nature-relatedness.
We
explore
whether
entheogenic
uses
ayahuasca
in
settings
co-produced
between
Indigenous
and
Western
knowledges
may
also
foster
relationality
sustainability
transformations
across
ontology,
praxis,
epistemology.
A
survey
74
English-speaking
individuals
who
attended
Amazonian
healing
ceremonies
at
the
Takiwasi
Center
Peru,
along
11
semi-structured
interviews
a
discussion
circle
revealed
unexpected
personal
shifts
towards
relationality.
Beyond
expected
increase
nature-relatedness,
participants
reported
boundary
dissolution
changes
their
perceptions
self,
leading
them
to
experience
nature
non-human
beings
as
having
spiritual
or
human-like
agency.
blurring
perceived
boundaries
themselves
challenged
materialist
ontologies
which
they
had
been
educated
socialized.
In
terms
both
epistemologies
enhanced
relational
thinking
embodiment
Inner-outer
ensued
from
post-ceremonial
integration
'plant's
teachings'
into
participants'
daily
lives.
discuss
our
findings'
contributions
emerging
field
inner
turn
sustainability.
Potential
benefits
scaling
plant-based
need
be
measured
against
impacts
on
Amazon
rainforest
its
biocultures.
Язык: Английский